Sabine D. Brookman-May: MA supports EFS as a surrogate for OS in Muscle invasive bladder cancer after neoadjuvant treatment

Sabine D. Brookman-May shared a post on X:

”This MA supports Event-free survival as a surrogate for Overall survival in MIBC after neoadjuvant treatment.

Strong association of Event-free survival + Overall survival for treatment effects (R2 0.94) + survival outcome

Significant association between 1 year Event-free survival/3 year Overall survival, 3 year Event-free survival/5 year Overall survival, median Event-free survival/Overall survival Bladder Cancer ”

Source: Sabine D. Brookman-May/X

Sabine D. Brookman-May is the Vice President of Bladder Cancer Development, Research and Development at Janssen Pharmaceutical Companies of Johnson & Johnson. She also serves as a professor of Urology at Ludwig Maximilian University of Munich, specializing in Urology, Oncology, and Sports and Exercise Medicine.